Dr. Hessam A. Aazami

General Practice
101 Family Medical Group,a Professional Corp
22030 Sherman Way, Suite 101, 
Canoga Park, CA 
 (2308.9 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
101 Family Medical Group,a Professional Corp
22030 Sherman Way, Suite 101, 
Canoga Park, CA 
 (2308.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Hessam Aazami is a General Practice provider in Canoga Park, California. His top areas of expertise are Vitamin D Deficiency, Osteoarthritis, High Cholesterol, and Type 2 Diabetes (T2D).

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
General Practice
Licenses
General Practice in CA
Hospital Affiliations
Northridge Hospital Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

101 FAMILY MEDICAL GROUP,A PROFESSIONAL CORP
22030 Sherman Way, Suite 101, Canoga Park, CA 91303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel
AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel
Enrollment Status: Completed
Publish Date: September 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection
Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

4 Total Publications

Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Journal: JAMA network open
Published: July 14, 2022
Similar Doctors
Expertise in
9
conditions
Dr. Nigel J. Cairns
General Practice
Expertise in
9
conditions
Dr. Nigel J. Cairns
General Practice
1314 N Hayworth Ave, 301, 
West Hollywood, CA 
 (15.8 mi)
323-874-9321
Languages Spoken:
English

Nigel Cairns is a General Practice provider in West Hollywood, California. Dr. Cairns is highly rated in 9 conditions, according to our data. His top areas of expertise are Dementia, Alzheimer's Disease, Lewy Body Dementia (LBD), and Parkinson's Disease.

Expertise in
28
conditions
Dr. Ali Hadadz
General Practice
Expertise in
28
conditions
Dr. Ali Hadadz
General Practice

Beverly Hills Medical Corporation

4560 Admiralty Way, Suite 303, 
Marina Del Rey, CA 
 (17.8 mi)
310-274-5510
Languages Spoken:
English
See accepted insurances

Ali Hadadz is a General Practice provider in Marina Del Rey, California. Dr. Hadadz is highly rated in 28 conditions, according to our data. His top areas of expertise are Sepsis, Lymphangitis, Hospital-Acquired Pneumonia, Gastrostomy, and Thyroidectomy.

Expertise in
5
conditions
Dr. Bhaveen H. Kapadia
General Practice
Expertise in
5
conditions
Dr. Bhaveen H. Kapadia
General Practice
2000 W Washington Blvd, 
Los Angeles, CA 
 (20.7 mi)
323-212-5775
Experience:
14+ years
Languages Spoken:
English
Accepting New Patients

Bhaveen Kapadia is a General Practice provider in Los Angeles, California. Dr. Kapadia has been practicing medicine for over 14 years is highly rated in 5 conditions, according to our data. His top areas of expertise are Osteonecrosis, Kienbock's Disease, Osteoarthritis, Knee Replacement, and Hip Replacement. Dr. Kapadia is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile